Considerations and development of topical microbicides to inhibit the sexual transmission of HIV

被引：109

作者：

Turpin, JA ^{[1
]}

机构：

[1] TherImmune Res Corp, Dept Immunol & Infect Dis, Gaithersburg, MD 20797 USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2002年 / 11卷 / 08期

关键词：

AIDS; BufferGel; C31G; cervix; cyanovirin-N; drug discovery; HIVPRO; 2000; STD; topical microbicide; transmission; UC-781; vagina; women;

D O I：

10.1517/13543784.11.8.1077

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The increased incidence of HIV/AIDS disease in women aged 15 - 49 years has identified the urgent need for a female-controlled, efficacious and safe vaginal topical microbicide. To meet this challenge, new topical microbicide candidates consisting of molecules or formulations that modify the genital environment (BufferGel(TM), engineered Lactobacillus, over-the-counter lubricants), surfactants (C31D/Savvy(TM) sodium dodecyl sulfate, sodium lauryl sulfate), polyanionic polymers (PRO 2000, beta-cyclodextrin, Carraguard(TM) CAP, D2S, SPL-7013), proteins (cyanovirin-N, monoclonal antibodies, thromspondin-1 peptides, Pokeweed antiviral protein and others), reverse transcription inhibitors (PMPA [Tenofovir(TM)), UC-781, SJ-3366, DABO and thiourea) and other molecules (NCp7-specific virucides, chemokine receptor agonists/ antagonists, WHI-05 and WHI-07) are currently being investigated for activity, safety and efficacy. This review will assess the development of these molecules in the context of cervicovaginal defences and the clinical failure of nonoxynol-9.

引用

页码：1077 / 1097

页数：21

共 262 条

[71] The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding [J].

DeVreese, K ;

Reymen, D ;

Griffin, P ;

Steinkasserer, A ;

Werner, G ;

Bridger, GJ ;

Este, J ;

James, W ;

Henson, GW ;

Desmyter, J ;

Anne, J ;

DeClercq, E .

ANTIVIRAL RESEARCH, 1996, 29 (2-3) :209-219

[72] Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides [J].

Di Fabio, S ;

Giannini, G ;

Lapenta, C ;

Spada, M ;

Binelli, A ;

Germinario, E ;

Sestili, P ;

Belardelli, F ;

Proietti, E ;

Vella, S .

AIDS, 2001, 15 (17) :2231-2238

[73] Beyond receptor expression: The influence of receptor conformation, density, and affinity in HIV-1 infection [J].

Doms, RW .

VIROLOGY, 2000, 276 (02) :229-237

[74] The plasma membrane as a combat zone in the HIV battlefield [J].

Doms, RW ;

Trono, D .

GENES & DEVELOPMENT, 2000, 14 (21) :2677-2688

[75] AMD310, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor [J].

Donzella, GA ;

Schols, D ;

Lin, SW ;

Esté, JA ;

Nagashima, KA ;

Maddon, PJ ;

Allaway, GP ;

Sakmar, TP ;

Henson, G ;

De Clercq, E ;

Moore, JP .

NATURE MEDICINE, 1998, 4 (01) :72-77

[76] A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5 [J].

Dragic, T ;

Trkola, A ;

Thompson, DAD ;

Cormier, EG ;

Kajumo, FA ;

Maxwell, E ;

Lin, SW ;

Ying, WW ;

Smith, SO ;

Sakmar, TP ;

Moore, JP .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) :5639-5644

[77] Vaccine development against HIV-1 - Current perspectives and future directions [J].

Edgeworth, RL ;

Juan, HS ;

Rosenzweig, JA ;

Nguyen, NL ;

Boyer, JD ;

Ugen, KE .

IMMUNOLOGIC RESEARCH, 2002, 25 (01) :53-74

[78] CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain [J].

Edinger, AL ;

Mankowski, JL ;

Doranz, BJ ;

Margulies, BJ ;

Lee, B ;

Rucker, J ;

Sharron, M ;

Hoffman, TL ;

Berson, JF ;

Zink, MC ;

Hirsch, VM ;

Clements, JE ;

Doms, RW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (26) :14742-14747

[79] Antimicrobial activity of human cervical mucus [J].

Eggert-Kruse, W ;

Botz, I ;

Pohl, S ;

Rohr, G ;

Strowitzki, T .

HUMAN REPRODUCTION, 2000, 15 (04) :778-784

[80]

Elias CJ, 1996, AIDS, V10, pS43

← 3 4 5 6 7 8 9 10 11 12 →